Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study

OBJECTIVE: Due to a high efficacy in clinical trials, sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and effectiveness of these regimens for GT2 in HCV-TARGET participants. DESIGN: HCV-TARGET...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gut
Main Authors: Welzel, Tania M, Nelson, David R, Morelli, Giuseppe, Di Bisceglie, Adrian, Reddy, Rajender K, Kuo, Alexander, Lim, Joseph K, Darling, Jama, Pockros, Paul, Galati, Joseph S, Frazier, Lynn M, Alqahtani, Saleh, Sulkowski, Mark S, Vainorius, Monika, Akushevich, Lucy, Fried, Michael W, Zeuzem, Stefan
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Hepatology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5595101/
https://ncbi.nlm.nih.gov/pubmed/27418632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2016-311609
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados